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Knowledge of the host response to the novel coronavirus SARS-CoV-2 remains limited,
hindering the understanding of COVID-19 pathogenesis and the development of
therapeutic strategies. During the course of a viral infection, host cells release
exosomes and other extracellular vesicles carrying viral and host components that can
modulate the immune response. The present study used a shotgun proteomic approach
to map the host circulating exosomes’ response to SARS-CoV-2 infection. We
investigated how SARS-CoV-2 infection modulates exosome content, exosomes’
involvement in disease progression, and the potential use of plasma exosomes as
biomarkers of disease severity. A proteomic analysis of patient-derived exosomes
identified several molecules involved in the immune response, inflammation, and
activation of the coagulation and complement pathways, which are the main
mechanisms of COVID-19–associated tissue damage and multiple organ dysfunctions.
In addition, several potential biomarkers—such as fibrinogen, fibronectin, complement C1r
subcomponent and serum amyloid P-component—were shown to have a diagnostic
feature presenting an area under the curve (AUC) of almost 1. Proteins correlating with
disease severity were also detected. Moreover, for the first time, we identified the presence
of SARS-CoV-2 RNA in the exosomal cargo, which suggests that the virus might use the
endocytosis route to spread infection. Our findings indicate circulating exosomes’
significant contribution to several processes—such as inflammation, coagulation, and
immunomodulation—during SARS-CoV-2 infection. The study’s data are available via
ProteomeXchange with the identifier PXD021144.
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1 INTRODUCTION
The novel coronavirus disease (COVID-19) is now responsible
for over one million deaths worldwide (COVID-19 Data in
Motion, 2020). The disease’s clinical presentation following
infection is challenging, ranging from asymptomatic patients
or mild-to-moderate respiratory infections in individuals with
atypical pneumonia. Peculiar features of acute respiratory distress
syndrome (ARDS) require admission to intensive care units and
mechanical ventilation. Although respiratory failure is the most
common clinical presentation of severe COVID-19 cases,
dysfunctions of other organs—including the kidneys and
heart—have also been reported (Wu et al., 2020). The SARS-
CoV-2 virus can infect multiple cell types, including lung
epithelial cells, lymphocytes, and other types of leukocytes
subsets (Bost et al., 2020). Moreover, Varga et al., (2020)
demonstrated that SARS-CoV-2 could enter the endothelial
cells of several organs; notably, endothelial infection is
responsible for viral dissemination and triggering of the
coagulation and complement cascades, which are key elements
in the host’s thromboinflammatory response and the
development of multiple organ failures (Guglielmetti et al.,
2020; Noris et al., 2020). In our previous work we used a
comprehensive untargeted metabolomic and lipidomic
approach to capture the host response to SARS-CoV-2
infection, providing evidence that lipids and metabolic
dysfunction are strongly involved in COVID-19 (Barberis
et al.,2020).
Considering the wide clinical presentation of COVID-19, the
scientific community still needs to improve its knowledge about
optimal prevention, early diagnosis, and adequate therapeutic
options. In this scenario, extracellular vesicles (EVs) may
represent an important tool for COVID-19 management. EVs
are micro-particles released from different types of activated cells,
and they play a key role in the mechanisms of intercellular cross-
talk through the direct transfer to target cells of proteins,
receptors, lipids, organelles, and genetic materials such as
mRNA and microRNA. EVs are present in different body
fluids—including plasma, urine, saliva, and
liquor—increasingly offering an opportunity to apply OMIC
technologies in order to study the host response to viral
infections and for biomarker discovery. Proteomics technology
has been widely used to characterize and study EVs (Bandu et al.,
2019; Choi et al., 2015; Xu et al., 2020; Adamo et al., 2019;
Bonafede et al., 2019). EVs can be classified into three main
families: 1) exosomes that originate from multivesicular bodies,
ranging in size from 30 to 150 nm; 2) microvesicles or shedding
vesicles released by cells through a membrane-sorting process
promoted by enzymes such as flippase, floppase, and scramblase
and characterized by a size larger than exosomes (150–1,000 nm);
and 3) apoptotic bodies that are larger than exosomes and
microvesicles and that are released by cells undergoing
programmed cell death (Camussi et al., 2013).
In recent years, EVs isolation and characterization protocols
have considerably improved (Théry et al., 2018), offering new
opportunities to study their roles both as biomarkers and as
mediators of several human diseases (Maione et al., 2020). Based
on these considerations, this study aimed to characterize—via
proteomic analysis—any alterations of exosome content upon
SARS-CoV-2 infection as well as the potential use of plasma
exosomes as biomarkers to monitor SARS-CoV-2 infection
severity. Moreover, the identification of several molecules
involved in processes such as immune response, and
inflammation, the activation of coagulation and complement
pathways could link circulating exosomes to COVID-




The presence of viral RNA in the exosome cargo was investigated
using reverse transcription-droplet digital polymerase chain
reaction (RT-ddPCR). RT-ddPCR enables a significant gain in
dynamic range while decreasing the cost of analysis. In addition,
it is more sensitive than qPCR, and it provides more accurate
data—especially at low target copy numbers (Rački et al., 2014).
Analysis of exosome content purified from critical and non-
critical patients revealed the presence of SARS-CoV-2 RNA in the
exosomal cargo. We found viral material that ranges from 15 to
88 copies/10 µl with no significant differences between the two
groups. No viral material was detected in healthy subjects.
2.2 Proteomic Analysis of Plasma-Derived
Exosomes From COVID-19 Patients
Untargeted proteomic analysis was performed on plasma-derived
exosomes from 17 SARS-CoV-2 positive patients and seven
healthy controls. The patients enrolled in this study resided in
Northern Italy, which was the COVID-19 pandemic’s Italian
epicenter.
We divided our patient group in two cohorts: critical (patients
with respiratory failure who were admitted to intensive care units,
requiring mechanical ventilation), and non-critical (all other
patients, with mild to severe respiratory failure, requiring
oxygen supplementation but neither invasive nor noninvasive
mechanical ventilation). Out of 17 patients, seven patients were in
critical condition, and 10 were in non-critical condition. Critical
COVID-19 patients’ blood levels of white blood cells (WBCs) and
eosinophil were significantly higher than non-critical patients.
On the contrary, we found a slight increase in red blood cells and
lymphocyte counts among non-critical COVID-19 patients
(Supplementary Table S1).
Figure 1 provides an overview of this study’s experimental
design. A brief description follows here. Exosomes were isolated
from plasma. The purification of the exosomes was subjected to
several control analyses. Nanosight and Western blotting were
employed to characterize the quality of the method of
purification; these analyses, which were performed only on
healthy subjects for safety reasons, confirmed the isolation of
exosomes with a size ranging from 30 to 100 nm (peak 37.70 ±
3 nm) and a concentration of 3x1011 particles/ml
(Supplementary Figure S1). In addition, the typical exosomal
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markers CD9 and CD63 were detected, confirming these vesicles
as exosomes.
Exosomal proteins were then extracted, digested, and analyzed
using a nano-liquid chromatography/tandem mass spectrometry
(nanoLC-MS/MS). The results were elaborated using
bioinformatics tools to highlight the main functions and
pathways associated with the host response to SARS-CoV-2
infection.
The validation of potential biomarkers was then performed
using a microLC-MS/MS on 36 COVID-19 patients, including
non-critical (23) and critical (13) subjects, and on 39 non-
COVID-19 patients, including 6 critical patients, 8 non-
critical patients, 7 healthy subjects and 7 healed COVID-19
subjects.
2.3 Circulating Exosomes in COVID-19
Patients Have a Specific Proteomic
Signature
To identify the proteins potentially involved in the development
of SARS-CoV-2 infection and in any immunomodulatory
functions mediated by circulating exosomes, plasma exosomes
from COVID-19 patients with varying disease severity were
analyzed using shotgun proteomic analysis.
A total of 913 different proteins were identified in plasma
exosomes; among them, 281 were found in critical, non-critical,
and healthy subjects, as Figure 2 shows. Interestingly, non-
critical patients are characterized by the presence of a higher
number of proteins (706), while a similar number of proteins
were identified in critical patients (478) and healthy subjects (454)
(Supplementary Table S2).
By analyzing exosomal cargo, we found that it was mainly
characterized by the presence of extracellular, exosomal,
lysosome, and cytoskeleton proteins (Figure 2B). Moreover,
these proteins are involved in transport activity, complement
activity, protease inhibitor activity, extracellular matrix structural
constituents, and defense/immunity activity (Figure 2C).
Interestingly, some proteins are associated with immune
response and coagulation (complement activity, immune
response, regulation of complement activation, Fc-gamma
receptor signaling pathway, immunoglobulin production, and
antimicrobial humoral response), as Figure 2D shows.
To assess overall differences between exosomes from COVID-
19 patients and healthy subjects, protein abundances were
FIGURE 1 |Overview of this study’s experimental design: plasma exosomes from 10 non-critical COVID-19 patients, seven critical COVID-19 patients, and seven
healthy subjects were isolated using a commercial kit. The exosomes’ protein content was analyzed using proteomics analysis (nanoLC-HRMS), and the identified and
modulated proteins were elaborated with bioinformatics in order to identify the host-derived exosome response to SARS-CoV-2 and its associated pathways. The
analysis suggested the presence of new biomarkers. The validation of potential exosomal biomarkers was performed on an external cohort of patients using a
proteomics approach on a microLC-HRMS. 36 COVID-19 patients, including non-critical (23) and critical (13) subjects, and on 28 non-COVID-19 patients, including 6
critical patients, 8 non-critical patients, 7 healthy subjects and 7 healed COVID-19 subjects were analyzed.
Frontiers in Molecular Biosciences | www.frontiersin.org February 2021 | Volume 8 | Article 6322903
Barberis et al. Exosomes Response to COVID-19
analyzed using multivariate statistical analysis. Principal
component analysis (PCA)—in particular, the first and second
principal components—clearly separated the samples according
to the groups. The first component explained the differences
between COVID-19 samples (red and yellow dots) and non-
COVID-19 samples (green dots), while the second component
mainly explained the differences between in disease severity
(Figure 3A). Figure 3B reports a bi-plot of the scores and
FIGURE 2 | Plasma-exosomes protein content. A Venn diagram (A) of identified proteins in critical and non-critical COVID-19 patients and in healthy subjects. Gene
ontology classification of identified proteins based on body component (B), molecular function (C), and biological process (D) was also used to assess the functions
associated to identified proteins.
FIGURE 3 | Principal component analysis. The score plot (A) of PC1 and PC2 shows a clear separation of healthy subjects (green dots) from critical COVID-19
patients (red dots) and non-critical (yellow dots) COVID-19 patients. (B) The bi-plot of the scores (black) and loading (red) of PC1 and PC2 reported the correlation
between the severity of the disease and the expression of proteins.
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individual proteins’ loading information. The plot reports the
proteins that are “driving the separation” between the patient
groups. For example, interestingly, CRP protein
(CRP_HUMAN) was able to discriminate positive patients
from non-positive patients but also critical patients from
non-critical patients.
The samples were also classified using a supervised partial
least square discriminant analysis (PLS-DA), which was
exploited to achieve maximum separation between the two
patient groups (Figure 4A). The most predictive or
discriminative features that are potentially useful in helping
sample classification were also determined through the VIP
(variable of importance in projection) score. The VIP score
summarized the most prominent proteins contributing to the
observed phenotypic variations in the COVID-19 plasma
exosomes (Figure 4B). Proteomics differences between the
three groups of samples were mostly due to haptoglobin
(HPT_HUMAN), C-reactive protein (CRP_HUMAN), Beta-
2-glycoprotein 1 (APOH_HUMAN), and Complement factor
H (CFAH_HUMAN). The dendrogram of hierarchical
clustering of protein abundance in exosomes from critical
patients (red), non-critical patients (yellow), and healthy
subjects (green) confirmed that exosomal proteins correlated
with the SARS-CoV-2 infection and with the disease’s severity
(Figure 4C).
2.4 Exosomal Proteins are Strongly Involved
in the Host Response to SARS-CoV-2
Next, we performed a univariate analysis of quantified proteins
using the relative abundance of 518 proteins quantified in all
samples. A total of 157 proteins were modulated in exosomes
from critical COVID-19 patients compared to healthy subjects,
while 97 proteins were regulated in non-critical patients (p-value
< 0.05, fold change > 1.3). Volcano plots (Figure 5A and
Figure 5B) showed the most significant differences among
proteins and the positive or negative fold-changes in exosomes
from critical and non-critical COVID-19 patients compared to
the healthy group. To summarize the univariate results, we used a
heat map (Figure 5C) to display the fold changes of the top
modulated proteins. This heat map allowed visualization of the
three clusters of samples and different protein levels. The
complete list of modulated proteins is reported in
Supplementary Tables S1, S2. The top regulated proteins in
both critical and non-critical patients, compared to healthy
subjects, mainly included inflammatory, immune-response,
FIGURE 4 |Modulated exosomal proteins in SARS-CoV-2 infection. Volcano plots of quantified proteins (A and B) reporting p-value and fold change. A total of 157
and 97 proteins were modulated in critical (A) and non-critical (B) COVID-19 patients, respectively (p-value < 0.05 and fold change > 1.3). Hierarchical heat maps of
quantified proteins (C) highlighting the three clusters of samples, with critical COVID-19 patients in red, non-critical COVID-19 patients in yellow, and healthy subjects in
green.
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and coagulation proteins. In critical patients, C-reactive protein
(122-fold), alpha-1-acid glycoprotein 1 (38-fold), lysozyme C
(13-fold), titin (12-fold), and zinc-alpha-2-glycoprotein (12-
fold) were up-regulated while putative trypsin-6 (31-fold),
coiled-coil domain-containing protein 34 (18-fold), C4b-
binding protein alpha chain (18-fold), C4b-binding protein
beta chain (15-fold), and pre-mRNA-processing factor 19
(14-fold) were down-regulated. Among non-critical
COVID-19 patients, the top five up-regulated proteins were
haptoglobin (41-fold), C-reactive protein (40-fold), trypsin-3
(14-fold), adenomatous polyposis coli protein (11-fold), and
hyaluronan-binding protein 2 (10-fold) while
immunoglobulin kappa variables 1–5 (10-fold),
immunoglobulin heavy variables 3–64D (7-fold), fibrinogen
gamma chain (5-fold), C4b-binding protein alpha chain (5-
fold), and C4b-binding protein beta chain (5-fold) were
under-expressed.
2.5 Circulating Exosomes in COVID-19
Patients may Modulate Immune Response,
Inflammation, and Coagulation Pathways
To obtain a global overview of the exosome proteomic response in
COVID-19, modulated proteins were analyzed with bioinformatics
tools. Ingenuity pathway analysis (IPA) was employed to identify the
main pathways, biological processes,molecular functions, and cellular
component associated with SARS-CoV-2 infection. The canonical
pathways involved in the host response mainly related to immune
response, inflammation, and coagulation. The chord diagrams in
Figure 6A,B report the top 10 pathways and their relative proteins
involved in critical (6A) and non-critical (6B) patients. The main
pathways involved in non-critical and critical patients were the
complement system pathway, acute-phase response signaling, the
coagulation system, the LXR/RXR activation pathway, the extrinsic
and intrinsic prothrombin activation pathway, the FXR/RXR
activation pathway, IL-12 signaling and production in
macrophages, the production of nitric oxide and reactive oxygen
species inmacrophages, and clathrin-mediated endocytosis signaling.
As Figure 6C shows, some pathways were more altered in non-
critical patients—specifically, acute phase response signaling, LXR/
RXR, and FXR/RXR activation.Meanwhile, other pathways—such as
the complement system, the coagulation system, and the extrinsic and
intrinsic prothrombin activation pathway—were more altered in
critical patients.
Diseases and disorders analysis highlighted the involvement of
the inflammatory response and immunological disease, while
physiological system development and function elaboration
showed that the protein cargo is associated with a humoral
FIGURE 5 |Modulated exosomal proteins in SARS-CoV-2 infection. Volcano plots of quantified proteins (A and B) reporting p-value and fold change. A total of 157
and 97 proteins were modulated in critical (A) and non-critical (B) COVID-19 patients, respectively (p-value < 0.05 and fold change > 1.3). Hierarchical heat maps of
quantified proteins (C) highlighting the three clusters of samples, with critical COVID-19 patients in red, non-critical COVID-19 patients in yellow, and healthy subjects
in green.
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immune response and immune cell trafficking (Figure 6D and
Figure 6E).
2.6 Upstream Analysis Highlighted the
Relation Between Inflammation and Protein
Cargo
To predict the upstreammolecules (transcription factor, microRNA,
etc.) that could play a role in the observed proteomemodulation and,
thus, in the host response to SARS-CoV-2 infection, we performed
upstream regulator analysis through IPA software. IPA analysis
suggested that interleukin IL-6 (IL-6) and transforming growth
factor (TGF)-beta1 (TGFB1) are the most significant upstream
regulators (Figure 7A and Figure 7C). Among other upstream
regulators, IL-1 was marked as a significantly activated regulator (z
score2.6) while IRF2 was predicted as an inhibited regulator (z
score-2.0), as Figure 7B,D show.
The dysregulation of IL-6–targeted genes (FGA, FGB, FGG,
FGL1, HSPA5, IGHM, LRG1, PPBP, S100A9, SAA4, SERPINA3,
SGK1, SPP1, TIMP1, VCAM1, A2M, AGT, APCS, and CP) and of
FIGURE 6 | Host-derived exosome response to SARS-CoV-2 infection. Circulating exosomes are characterized by proteins and pathways involved in
inflammation, immune response, and coagulation.
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TGFB1-targeted genes (VCAM1, TIMP1, SPP1, SGK1, SERPINA3,
PSEM4, LYVE1, KNG1, IGHM, HSPG2, HSPA5, GSN, FN1, FGG,
FGB, FGA, FCGR3A/FCGR3B, CP, CFH, C4BPB, C4BPA, C1R, and
ADAMTS2) may contribute to SARS-CoV-2–related dysfunctions.
As mentioned above, most of these regulated genes are involved in
inflammation, immune response, and coagulation.
2.7 Association of Exosome Cargo with
Pathologically Relevant Clinical Indices
We then evaluated whether exosomal protein cargo in COVID-19
patients significantly correlated with CRP and d-dimer levels,
platelets, neutrophil, and monocytes counts. Spearman
correlations were performed, and only correlations with
p < 0.05 were considered and shown in Supplementary Table
S5–S9. We found that circulating CRP levels positively correlated
with CRP, IBP2, CHI3L1, FGB, FHR5, IGHV3-73, FGG, PRSS2,
CFP, CFH, CD163, FCGBP, and CAT exosomal proteins, which
are linked to inflammation, complement activation, and
pulmonary fibrosis (Lu et al., 2011). Fibronectin, alpha-2-HS-
glycoprotein, and alpha-1-acid glycoprotein 1 protein positively
correlated with d-dimer levels, and platelet counts positively
correlated with TIMP1, COL6A3, SPINK1, IGFBP4, IGHV1-8,
NCAM1, COL18A1, APOA2, CFB, and MYH7 exosomal
proteins, which are involved in platelets’ aggregation,
adhesion, or activation and complement activation (Stecher
et al., 1986).
Regarding neutrophil count, we found an increase in
neutrophil among critical COVID-19 patients, and our
analysis of exosomal cargo revealed a positive correlation with
FGA protein, which is implicated in neutrophil activation (Rubel
et al., 2001) but also with TPI1 protein, which has already been
found in exosome cargo (Vargas et al., 2016), and with other
inflammatory proteins (i.e., SAA1, coagulation factor XI, etc.).
Monocyte counts positively correlated with IGFALS, CFP,
CLU, and SERPINC1 exosomal proteins, which are involved
in the migration and chemotaxis of human monocytes (Peix
et al., 2018).
2.8 Circulating Exosomes are Potential
Biomarkers of COVID-19
Potential biomarkers were explored by carefully analyzing
modulated proteins’ distribution and by using ROC curves.
FIGURE 7 | Canonical pathway analysis. A Chord diagram presenting a pathway analysis of significantly altered proteins in response to SARS-CoV-2 infection in
critical (A) and non-critical (B) patients. Each pathway’s width is determined by the number of proteins associated with each pathway. Canonical pathways’ significance
(-log(p-value)) was also compared (C): this analysis showed similar exosome responses in critical and non-critical patients. The diseases and disorders analysis (D),
molecular and cellular functions (E), and physiological system development and function elaboration (F) are also shown.
Frontiers in Molecular Biosciences | www.frontiersin.org February 2021 | Volume 8 | Article 6322908
Barberis et al. Exosomes Response to COVID-19
We firstly evaluated modulated proteins obtained from the
discovery phase. Interestingly, we found that the abundance of
several proteins directly correlated with the disease’s severity. In
particular, critical patients displayed higher levels of CRP,
A1AG1, A1AG2, CXCL7, SAMP, and ZA2G and lower levels
of CCD34, C4BPA, and GELS than non-critical patients (Figures
8A–I). In addition, this analysis reported the presence of several
proteins that are able to discriminate between COVID-19
patients and healthy subjects.
Biomarkers were validated on a new cohort of patients that
included not only COVID-19 critical (n13) and non-critical
(n26) patients and healthy subjects (n7), but also critical (n6)
and non-critical (n8) patients admitted for pneumonia and/or
respiratory failure with negative nucleic acid test results (NON-
COVID-19) and COVID-19 healed patients (n7). Interestingly,
fibrinogen proteins fibrinogen alpha chain (FIBA_HUMAN),
fibrinogen beta chain (FIBB_HUMAN) and fibrinogen gamma
chain (FIBG_HUMAN) showed an AUC value of 0.94 (sensitivity
(SE): 86%; specificity (SP): 97%), 0.90 (sensitivity (SE): 92%;
specificity (SP): 86%) and 0.93 (sensitivity (SE): 83%;
specificity (SP): 91%), respectively. In addition, fibronectin
(FINC_HUMAN), Complement C1r subcomponent
(C1R_HUMAN) and Serum amyloid P-component
(SAMP_HUMAN) showed an AUC value of 0.92 (sensitivity
(SE): 94%; specificity (SP): 82%), 0.93 (sensitivity (SE): 89%;
specificity (SP): 82%) and 0.91 (sensitivity (SE): 89%;
specificity (SP): 82%), respectively (Figure 8J–O).
We also compared modulated exosomal proteins with
regulated serum proteins in COVID-19 patients reported in
the literature (D’Alessandro et al., 2020; Shen et al., 2020;
FIGURE 8 | Upstream gene regulator analysis. IL-6 (A) and transforming growth factor (TGF)-beta1 (B) are the most significant upstream regulators. IL-1 resulted
significantly activated (z score2.6) while interferon regulatory factor 2 was predicted as an inhibited regulator (z score-2.0).
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Messner et al., 2020). Table 1 reports the list of common
differentially expressed proteins. Interestingly, more than 50%
of proteins (27 out of 50) presented the same direction of
modulation identified in previous research on serum
circulating proteins—even if the fold-change levels in plasma-
exosome were higher than in serum.
3 DISCUSSION
This study provides the first proteomic characterization of
plasma-derived exosomes from COVID-19 patients and
healthy controls. Participating patients were enrolled from a
hospital located in Northern Italy, the first western epicenter of
the COVID-19 pandemic. WBC, neutrophil, and eosinophil
counts were increased in critical COVID-19 patients while the
number of red blood cells, as well as lymphocytes, were
significantly decreased (Terpos et al., 2020). Exosomes and
EVs play significant roles in various biological functions and,
particularly, in both physiological and pathological processes
(Zhang et al., 2019). Indeed, they are associated with immune
responses, viral pathogenicity, pregnancy, cardiovascular
diseases, central nervous system–related diseases, and cancer
progression (Kalluri and LeBleu, 2020).Several examples of
scientific evidence have shown that viruses might use EVs to
enter uninfected cells (Urbanelli et al., 2019). During the course
of infections, EVs can convey pathogen molecules that serve as
antigens or agonists of innate immune receptors to induce host
defense and immunity or serve as regulators of host defense and
mediators of immune evasion (Kadiu et al., 2012; Schorey and
Harding, 2016).Our data reports, for the first time, the presence
of viral material in COVID-19 patients’ host exosomal cargo.
This finding suggests that SARS-CoV-2 may use the
endocytosis route to spread infection throughout the host.
We did not identify viral proteins via the purification of
exosomes; thus, we can conclude that viral particles were
not purified together with exosomes, suggesting that the
RNA material was originally present in the cargo. A very
recent study showed that exosomal microRNAs may drive
thrombosis in COVID-19 patients (Gambardella et al., 2020)
while Song and colleagues found that GM3-enriched exosomes
positively correlated with disease severity, suggesting that they
may participate in the pathological processes associated with
COVID-19 progression (Song et al., 2020). Moreover,
exosome-based strategies were also proposed to treat
COVID-19 (Hassanpour et al., 2020) or prevent SARS-CoV-
2 infection (Cocozza et al., 2020).
Our findings show that circulating exosomes are strongly
involved in the processes associated with SARS-CoV-2
infection. Interestingly, our proteomic analysis of plasma-
derived exosomes from COVID-19 patients revealed a specific
proteomic signature. This signature was particularly evident
using multivariate statistical analysis (PCA and PLS-DA),
which highlighted the presence of proteomic features that are
able to clearly discriminate between the samples, according to the
diagnosis. Bioinformatics analysis revealed the presence of
proteins related to the coagulation process, transport activity,
complement activity, protease inhibitor activity, and defense/
immunity protein activity.
Interestingly, exosomal proteins’ relative abundance in
COVID-19 patients significantly differed from healthy
subjects. Indeed, 157 and 97 proteins were significantly
modulated in critical and non-critical COVID-19 patients,
respectively. Our canonical pathway analysis performed on
modulated proteins revealed the involvement of pathways
TABLE 1 | Comparison of modulated exosomal proteins with regulated serum










A1BG Up Up − − Up
ACTB − Up − − Up
AHSG − Up Down − −
ALB Up − Down − −
APO2 Up − − Down −
APOD Up − − Up −
APOF − Up Up − −
APOH Down Up − Down −
C1R Down Down − − Up
C1S − Down − − Up
C4BPA Down Down − Up −
C9 Up − Up − −
CLEC3B − Down Down − −
CRP Up Up Up − Up
CST3 − Up Up − −
F13B Down Down Down − −
FCN2 Up − Down Down −
FGA Down Down - − Up
FGB Down Down - − Up
FGG Down Down - − Up
FN1 Down Down - − −
GSN Down Down Down − Down
HP Up − − − Up
IGHV1-2 Down − Up − −
IGHV3-15 − Down Up − −
IGHV3–23 Down Down Up − −
IGHV3–9 Down Down Up − −
IGHV4–28 − Down Up − −
IGHV4–38–2 Down − Up − −
IGKV1–5 Down − Up − −
IGKV4–1 Down − Up − −
ITIH1 − Down Down − −
ITIH2 − Down Down − −
ITIH3 Up − Down Up Up
ITIH4 Up − Down Up Up
LRG1 Up Up Up − −
LYZ − Up Up − −
ORM1 Up Up Up Up −
PGLYRP2 Down − Down − −
PON1 Up − Down − −
PPBP Up Up Down − −
S100A8 − Up Up − −
S100A9 − Up Up − −
SAA4 Up Up − Up −
SERPINA3 Up Up Up Up −
SERPINA6 − Up Down − −
SERPING1 Up Up Up − −
TIMP1 Up Up Up − −
VCAM1 Up Up − Up −
VWF − Down Up − −
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associated with immune response, coagulation, and
inflammation, as in Figure 9 summarizes.
The complement pathway is a double-edged sword for our
immune system: it may offer protection by favoring viral
clearance, but unrestrained activation may also result in
pathological acute and chronic inflammations, tissue injury,
and activation of the coagulation pathway (Noris et al., 2020).
Complement activation has been linked to the pathophysiology of
ARDS caused by various underlying diseases, and it has also been
associated with COVID-19 (Risitano et al., 2020). Chahar et al.
demonstrated that exosomes derived from respiratory syncytial
virus–infected cells were able to activate an innate immune
response by inducing cytokine and chemokine release from
human monocytes and airway epithelial cells (Chahar et al.,
2018). As Figure 6A,B show, we found a dysregulation of 17
proteins (C1QB, C1QC, C1R, C1S, C2, C3, C4A/C4B, C4BPA,
C4BPB, C5, C6, C8A, C8G, CFI, CR1, MBL2, SERPING1) in
critical patients associated with the complement system pathway
while, in non-critical patients, 11 proteins were modulated (C1R,
C4A/C4B, C4BPA, C4BPB, C8A, C8G, C9, CFH, CFI, MBL2, and
SERPING1). In addition, the complement system pathway
appeared more altered in critical patients (-log (p-value)27.6)
than non-critical patients (-log (p-value)17.7). Among
complement-related proteins, CFH and C4BPA had already
been identified as transcriptional markers associated with
severe SARS-CoV-2 infection: these molecules play central
roles in complement activation and innate immunity (Ramlall
et al., 2020). Moreover, we found an 2.5-fold increase of C9 in
non-critical patients and a down-regulation of CFH; these
findings suggest that, in critical COVID-19 patients, the C9
complement component might be impaired due to SARS-
CoV-2 infection, as has already been shown for the hepatitis C
virus (Kim et al., 2013). Interestingly, a global down-regulation of
proteins coding for antibodies such as IGHV1-2, IGHV3-15,
IGHV3-23, IGHV3-9, IGHV4-28, IGHV4-38-2, IGKV1-5, and
IGKV4-1 was especially found in critical COVID-19 patients,
suggesting the involvement of the humoral immune response, as
Rolla et al. (2020) have already shown in reporting a significantly
lower count of antibody-synthesizing lymphocyte among critical
COVID-19 patients. Our results provide the first evidence of
circulating exosomes’ potential immunomodulatory contribution
in response to SARS-CoV-2 infection.
Furthermore, our analysis highlighted the implication of
proteins in the acute-phase response pathway. The human
immune system plays a key role in the defense against
pathogens (Li et al., 2020). The acute-phase response is an
TABLE 2 | Characteristics of the patients included in the discovery phase study.
Variable Non-COVID-19 patients COVID-19 patients
Healthy Control (N=7) Total (N=17) Non-critical (N=10) Critical (N=7)
Sex (no.)
Male 2 8 5 3
Female 5 9 5 4
Age (year)
Mean ± SD 51.4 ± 4.8 64.3 ± 16.5 68.3 ± 19.7 58.7 ± 8.8
Range 43.0 − 56.0 37.0 − 97.0 37.0 − 97.0 47.0 − 70.0
Time from onset to admission (days)
Mean ± SD 5.2 ± 5.0 6.2 ± 5.8 3.6 ± 3.5
Range 1.0 − 18 1.0 − 18.0 1.0 − 9.0
Time from admission to severe (days)
Mean ± SD 3.8 ± 2.9
Range 1.0 − 8.0
Symptoms (n°)
Fever 8 4 4
Cough 6 5 2
Headache 0 0 0
Fatigue 1 1 0
Dyspnea 3 2 1
Diarrhea 2 1 1
Chest pain 1 1 0
Abdominal pain 1 0 1
Vomiting 1 1 0
Comorbidity (n°)
Hypertension 4 1 3
Diabetes 6 2 4
Respiratory system 9 6 3
Cardiovascular system 6 3 3
Other endocrine system 2 0 2
Chronic kidney 3 0 3
Digestive system 4 1 3
Oxygen saturation index (%)
Mean ± SD 93.4 ± 7.1 94.3 ± 4.4 92.1 ± 10.5
Range 71.0 − 99.0 86.0 − 99.0 71.0 − 98.0
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innate body defense activated during acute illnesses, and it
involves increased production of acute-phase proteins such
as CRP and cytokines. In the case of an infection, the
inflammatory response stimulates the liver to synthesize and
release anti-inflammatory proteins that suppress inflammation
and regulate immunity in the body (Gelain and Bonsembiante,
2019). As already reported, SARS-CoV-2 infected patients
show high levels of pro-inflammatory cytokines and
chemokines associated with pulmonary inflammation and
extensive lung involvement; such inflammation has also been
observed in SARS and MERS patients (Coperchini et al., 2020).
Other studies have reported an elevation in acute-phase
reactants among patients with COVID-19, including ESR,
C-reactive protein (CRP), serum amyloid A, and
ferritin—suggesting a rapid activation of the innate immune
response (Jamilloux et al., 2020). Moreover, serum changes in
acute-phase response proteins were used as indicators to
identify the degree and progression of COVID-19. A
significant increase in CRP and SAA content and a decrease
C3 and C4 content have been associated with the disease’s
severity (Li and Chen, 2020). In our study, among acute-phase
proteins, exosomal CRP resulted in 122-fold and 40-fold up-
regulation in critical and non-critical patients, respectively. A
preliminary analysis of hematological and inflammatory
parameters was associated with elevated CRP, IL-6, and NLR
values and with worse outcomes as well as a lack of response to
treatment (Montesarchio et al., 2020; Khinda et al., 2020). High
C-reactive protein independently predicted the risk of
mortality in a cohort of 183 COVID-19 patients (Rolla et al.,
2020). Another study identified increased CRP levels in a
limited number (31.0%) of COVID-19 patients (Ren et al.,
2020). While high CRP levels were already reported during
inflammation processes, our results indicate that CRP can be
transported to other cells through EVs, thus driving the
infection’s inflammatory effect. Alpha-1-acid glycoprotein
protein (AGP), which is one of the major acute-phase
proteins in humans, was up-regulated in both critical and
non-critical patients. During the acute-phase response, the
serum concentration of AGP increases as a liver hepatocytes
response to the cytokines that are released by monocytes and
other cells in the early phase of inflammation or infection (van
Dijk et al., 1991). Alpha 1-antichymotrypsin
(AACT_HUMAN) is another acute-phase protein that was
found to be overexpressed in critical COVID-19 patients.
TABLE 3 | Characteristics of the patients included in the validation phase study.
Variables COVID-19 Non-COVID-19














Male 21 13 8 12 5 3 2 2
Female 15 10 5 17 3 3 6 5
Age-year
Mean ± SD 65.6 ±17.6 66.5 ± 20.6 53.8 ± 10.7 60.4 ± 17.0 76 ± 12.9 68.6 ± 8.9 50.4 ± 5.4 46.8 ± 17.6
Range 35.0 − 101.0 35.0 − 101.0 49.0 − 84.0 30.0 − 96.0 59.0 − 96.0 56.0 − 82.0 43.0 − 56.0 30.0 − 72.0
Time from Onset to Admission, Days
Mean ± SD 4.3 ± 4.5 4.5 ± 5.0 4 ± 3.6 4.8 ± 6.1 5.7 ± 7.0 1.0 ± 0.0
Range 1.0 − 19.0 1.0 − 19.0 1.0 − 10.0 1.0 − 21.0 1.0 − 21.0 1.0 − 1.0
Time from Admission to Severe, Days
Mean ± SD 3.1 ± 2.8 3.0 ± 4.9
Range 1.0 − 8.0 1.0 − 13.0
Symptoms–no.
Fever 18 11 7 3 1 2
Cough 16 11 5 3 0 3
Headache 0 0 0 2 0 2
fatigue 3 2 1 3 0 3
Dyspnea 8 6 2 5 1 4
Diarrhea 4 2 2 0 0 0
Chest pain 1 1 0 2 0 2
Abdomial Pain 2 1 1 0 0 0
vomit 1 1 0 1 1 0
Comorbility–no.
Hypertension 10 5 5 6 4 2
Diabetes 8 4 4 1 0 1
Respiratory system 4 2 2 1 1 0
Cardiovascolar
system
16 8 8 1 0 1
Other Endocrine
system
1 0 1 8 8 0
Chronic Kidney 3 1 2 1 1 0
Oxygen saturation index–%
Mean ± SD 91.3 ± 7.4 93.3 ± 5.2 97.4 ± 9.6 92.1 ± 5.6 94.0 ± 4.1 85.5 ± 6.4
Range 71.0 − 99.0 81.0 − 99.0 71.0 − 98.0 81.0 − 99.0 87.0 − 99.0 81.0 − 90.0
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IL-12 signaling and production in macrophages pathways
were significantly altered in both critical and non-critical
patients, although we did not identify IL-12 protein directly in
exosome cargo. Experimental evidence has shown that IL-12
rapidly activates both innate and specific immune responses,
promoting host cellular responses, the clearance of the virus, and
host recovery from infection (Komastu et al., 1998).
Interestingly, we found a significant modulation of the MSP-
RON signaling pathway. This pathway contributes to the
macrophage-induced immune response in order to assist the
host in viral recognition via the macrophage stimulating protein
(MSP) and the transmembrane receptor kinase RON Protein
Tyrosine Kinase/Receptor d.
Coagulation’s involvement in SARS-CoV-2 infection has been
extensively reported in COVID-19 (Palumbo et al., 2020; Al-
Samkari et al., 2020). Proteins involved in platelet degranulation
were down-regulated in SARS-CoV-2–infected patients (Zheng
et al., 2020), together with the low platelet count associated with
severe COVID-19 and mortality (Lippi et al., 2020; Shen et al.,
2020). Our bioinformatics analysis demonstrated that exosomal
proteins are associated with the coagulation system pathway and
with the intrinsic and extrinsic prothrombin activation pathways.
Complement factors are able to increase tissue factor activity,
form activated thrombin from prothrombin, increase platelet
activity and aggregation, increase prothrombinase activity, and
release platelet-derived procoagulant granules (Fletcher-
Sandersjöö and Bellander, 2020).
Among the effects of the viral ACE2 used by SARS-CoV-2 for
cell entry, the connection between ACE2 and the Kallikrein/Kinin
system—which regulates coagulation, fibrinolysis, and
complement cascade—has resulted in great interest (Colarusso
et al., 2020). Indeed, ACE2 physiologically binds and cleaves Lys-
des-Arg9-Bradykinin and Des-Arg9 Bradykinin, which are
potent ligands of Bradykynin Receptor 1 in the lungs (van de
Veerdonk et al., 2020). When the virus blocks ACE2, the
degradation of bradykinin cannot be performed, causing the
accumulation of bradykinin itself; consequently, bradykinin—a
product of high-molecular-weight kininogen—binds to its
receptor (bradikynin-1receptor), triggering acute inflammation
in the lungs due to the release of pro-inflammatory chemokines
and cytokines such as the well-known IL-6 (Colarusso et al.,
2020). Moreover, the kallikrein/kinin and renin-angiotensin
systems also play a thrombo-regulatory role (Fang and
Schmaier, 2020). Our data showed a two-fold up-regulation of
Kininogen-1 in the exosomes of COVID-19 patients. Kininogen-
1 itself has a relationship with the coagulation cascade, and it is
considered an anti-thrombotic target. Indeed, its gene deletion
has been associated with a reduced risk of induced thrombosis in
mice (Fang and Schmaier, 2020). Hemostatic and thrombotic
manifestations are common in critical COVID-19 patients, and
they are among the leading causes of death (Al-Samkari et al.,
2020 52), while a high number of venous thromboembolism
(VTE) events among severely ill patients with COVID-19
pneumonia has been observed worldwide (Fontana et al.,
2020). Relying on the role of Kininogen-1 and our findings,
we speculate that exosomes may serve as a reserve and carrier of
Kininogen-1.
Bioinformatic analysis has also pointed out the IL-6 and
TGFβ1 cytokines’ involvement as upstream regulators of
modulated protein. IL-6 is recognized as the main mediator of
the inflammatory and immune response initiated by SARS-CoV-
2 infection (Grifoni et al., 2020). As an upstream regulator of the
exosomal proteins in COVID-19 patients, we speculate that IL-6
may also affect protein secretion from cells through EVs. TGFβ1
is a pleiotropic cytokine with regulatory capabilities, and it is
involved in the resolution of the inflammatory response (Sanjabi
et al., 2009). The host response to infection could be regulated by
TGFβ1 with the help of a cytokine storm and the presence of
TNF, IL-1β, and IL-6 (Chen, 2020). Lung fibrosis is among the
clinical hallmarks of COVID-19 infection; indeed it was identified
FIGURE 9 | Box-plots and ROC curves for the best potential biomarkers identified using proteomic analysis of the exosome cargo. For (A–I), box-plots of proteins
that are well correlated with the disease’s severity are reported. Red dots indicate critical COVID-19 patients while yellow dots indicate non-critical COVID-19 patients.
Fibrinogen alpha chain (J), fibrinogen beta chain (K), fibrinogen gamma chain (L) fibronectin (M), Complement C1r subcomponent (N) and Serum amyloid P-component
(O) were confirmed as good biomarkers in the validation. Purple dots indicate NON-COVID-19 patients while green and blue dots and indicate healthy and healed
subjects, respectively.
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as a leading cause of pulmonary damage, as reported by Polak
et al., (2020), who showed that 22% of patients presented a
fibrotic pattern of lung injury characterized by interstitial
fibrosis. Our data also suggest a correlation between TGFβ1,
glucose, and exosomes. Interestingly, a correlation between a high
concentration of glucose and worsening COVID-19 has been
reported; for example, diabetic patients with uncontrolled glucose
levels are evidently more prone to manifesting COVID-19
complications and consequent increased mortality—though the
molecular mechanism currently remains undetermined (Zhu
et al., 2020). Prolonged and uncontrolled hyperglycemia was
also described as a prognostic factor (Brufsky, 2020). Most
importantly, exosomes’ key role was already reported in the
pathogenesis of diabetes nephropathy: high glucose leads to
increased excretion of exosomes from macrophages through
the TGF-β1 mRNA, which acts as a bridge between
macrophages and mesangial cells (Zhu et al., 2019). A similar
connection might also be applied to COVID-19, between
macrophages and lung cells, even if other research is needed
to investigate this hypothesis.
We also investigated exosomal proteins’ potential role as
diagnostic biomarkers for COVID-19 infection and disease
severity. Several exosomal proteins such as CRP, A1AG1,
A1AG2, CXCL7, SAMP, and ZA2G proteins directly
correlated with the disease’s severity, as their increase among
critical patients showed, by suggesting a potential use of these
proteins for monitoring the disease’s outcome and, potentially,
any response to therapies. In line with our hypothesis, the
exosomal proteome was already investigated to monitor sepsis
progression (Xu et al., 2018) and HIV patients subjected to
antiretroviral therapy (Chettimada et al., 2018). Huan et al.
found that COVID-19 patients had significantly increased
SAA and CRP levels, suggesting that SAA could serve as a
biomarker to monitor the respiratory diseases’ progression
(Huan et al., 2020). CRP levels positively correlated with the
diameter of lung lesions and severe presentation (Wang, 2020;
Matsumoto et al., 2019) but also with an increased risk of organ
failure and death (Pierrakos and Vincent, 2010). Another
interesting protein that we found to be up-regulated in critical
patients is Fetuin-A. Exosomal Fetuin-A was already identified as
a novel urinary biomarker for detecting acute kidney injury. We
speculate that its up-regulation in critical COVID-19 patients can
explain kidney injury, which is often reported in severe patients
(Zhou et al., 2006).
Interestingly, the validation reported the presence of very good
biomarker candidates—such as fibrinogen alpha chain,
fibrinogen beta chain, fibrinogen gamma chain, fibronectin,
complement C1r subcomponent and serum amyloid
P-component—reporting an AUC from 0.94 to 0.91 with very
good AUC values (from 0.94 to 0.91).
Intriguingly, all fibrinogen components in plasma exosomes
were down-regulated in COVID-19 patients, suggesting an
altered coagulation activity that could reflect a compensatory
response to potential thrombotic manifestations.
Further, among the exosomal proteins modulated in SARS-
CoV-2 infection we found LYVE1, TIMP1 and CXCL7
(Figure 5C). This expression profile supports to some extent
the role of macrophage activation syndrome (MAS) as the main
driver of hyperinflammatory response in COVID-19 patients
(Schulert and Grom, 2015). Indeed, while LYVE-1-expressing
macrophages control arterial stiffness through modulation of the
metalloproteinase-dependent proteolysis of the MMP-9 matrix
(Lim et al., 2018), the expression of the MMPs inhibitor TIMP1 is
related to the frequency of pulmonary macrophages and is
involved in influenza-induced lung injury (Allen et al., 2018)
and CXCL7 is a known attractant of macrophages in lung
inflammation (Unver et al., 2015).
In addition, our data revealed the presence of several exosomal
proteins that present the same expression pattern as proteins
detected in the serum of COVID-19 patients. Serum proteomics
is usually performed on circulating serum proteins, with a bias
not to discriminate between proteins contained in the exosome
cargo used for cell-to-cell communication, and it may represent a
picture of the mechanisms involved in COVID-19. Exosomes’
role may be particularly relevant in COVID-19 because SARS-
CoV-2 infection is associated with tissue damage and multiple
organ dysfunctions, and circulating exosomes can potentially
reach several distant target cells and organs.
Taken together, our study’s findings provide the first evidence
that circulating exosomes are strongly modulated during
COVID-19 infection and might be involved in pathogenesis.
The presence of viral material in the exosomal cargo showed
that SARS-CoV-2 could use the cell-to-cell communication
system to spread infection in the host. Proteomic analysis of
plasma exosomes identified several molecules involved in
immune response, inflammation, and the activation of
coagulation and complement pathways, suggesting a significant
role for exosomes in the mechanisms associated with tissue
damage and multiple organ dysfunctions typical of COVID-19.
Another remarkable result emerging from these data is the
presence of several potential biomarkers that are well
correlated with the disease’s severity. Although, to date, ours is
the first study that characterizes the circulating exosomal proteins
and pathways from SARS-CoV-2 infected patients, future studies
are needed to determine the number and size of EVs in COVID-
19. Moreover, monitoring exosomal content during infection
may contribute to a better understanding of whether exosomes
support viral spreading or induce immunological protection.
4 MATERIALS AND METHODS
4.1 Patients
For the discovery phase plasma samples from 17 subjects,
admitted to Novara University Hospital for pneumonia and/or
respiratory failure fromMarch to April 2020 were collected at the
Emergency Department or at COVID-19 wards including the
Intensive Care Unit. All the patients had a confirmed diagnosis of
SARS-CoV-2 infection by reverse-transcriptase polymerase chain
reaction (RT-PCR).
We considered critical patients those with respiratory failure
admitted to the intensive care unit requiring mechanical
ventilation, while non-critical patients all other patients with
mild to severe respiratory failure requiring oxygen
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supplementation but neither invasive nor noninvasive
mechanical ventilation. All the patients were treated with
Lopinavir / Ritonavir (Kaletra) and Hydroxychloroquine.
Out of the 17 COVID-19 patients enrolled, 7 were critical and
10 non-critical. Healthy individuals (n7) were enrolled as
controls. For the validation phase 36 COVID-19 patients,
including non-critical (23) and critical (13) subjects, and on
39 non-COVID-19 patients, including 6 critical patients,
8 non-critical patients, 7 healthy subjects and 7 healed
COVID-19 subjects were used. The Institutional Review Board
(Comitato Etico Interaziendale Novara) approved this study.
Clinical characteristics of the patients involved in the study are
reported in Tables 2, 3.
4.2 Isolation of Plasma Exosomes
Exosomes were isolated using Exo-Spin exosome purification kit
for plasma (Cell Guidance Systems, UK). In brief, 250 μl of
plasma samples were centrifuged first at 300 g and then at
16000 g for 10 and 30 min, respectively, to remove platelets
and larger vesicles. Half the volume of Exo-Spin buffer was
added to the plasma samples, which were then mixed by
inverting and incubated at 4°C for 1 h before centrifugation at
16 000 g for 60 min. Exosome pellets were resuspended in 100 μl
phosphate-buffered saline (PBS) and purified using the Exo-Spin
column. Finally, exosome were eluted in 200 μl PBS.
4.3 Nanoparticle Tracking Analysis
(NanoSight NS300)
Particle size and concentration of plasma-derived exosomes were
analysed by NTA using the NanoSight Technology NS300. In
brief, exosomes were diluted in sterile saline buffer solution (1:
100) and analyzed by the Nanoparticle Analyses System using the
NTA 1.4 Analytical Software.
4.4 Western Blotting
Analysis of exosomes by immunoblotting was performed using
standard protocols: proteins were denatured, separated on 4–12%
polyacrylamide gels, transferred onto a nitrocellulose membrane
and probed with antibodies against tetraspanins CD9 (Santa Cruz
Biotechnology) and CD63 (Santa Cruz Biotechnology). The
immunocomplexes were visualized by chemiluminescence
using the Chemidoc MP imaging system (Bio-Rad
Laboratories). Signal intensity of the bands was measured by




Total RNA was extracted from 50 µl of plasma-derived exosomes
using NucleoZOL (Macherey-Nagel) following manufacturer’s
instruction.
SARS-CoV-2 RNA was quantified by means of the QX200TM
Droplet Digital TM PCR System (ddPCR, Biorad) using the Bio-
Rad SARS-CoV-2 ddPCR Kit and following manufacturer’s
instruction. Data were analyzed using the QuantaSoftTM 1.7.4
Software (Bio-Rad) and SARS-CoV-2 quantification was
expressed in number copies/10 µl of exosomes.
4.6 Immunodepletion of Ligh-Abundant
Plasma Proteins and Digestion
Exosomes were lysed using 200 μl of RIPA buffer (50 mm Tris
HCl pH 7.2, 0.05%SDS) and sonication. Proteins were then
precipitated overnight using cold acetone at −20°C. The pellet
was then resuspended using urea buffer and ammonium
bicarbonate. In order to improve the identification and
quantification of exosomal proteins we depleted high-
abundance proteins using the Seppro IgY14 spin column kit
(Sigma-Aldrich Inc., St. Louis, MO, USA) according to the
manufacturer’s procedure. The method was used to bind
human serum HSA, IgG, fibrinogen, transferrin, IgA, IgM,
haptoglobin, alpha 2-macroglobulin, alpha 1-acid glycoprotein,
alpha 1-antitrypsin, Apo A-I HDL, Apo A-II HDL, complement
C3 and LDL (ApoB) in order to increase low-abundance protein
identification. The samples were transferred into an Amicon
Ultra-0.5 mL 3 kDa centrifugal filter (Millipore, Billerica, MA,
United States) following the manufacturer’s procedure to collect
high molecular weight proteins. The samples were then subjected
to reduction with DTT 200 mM, to alkylation with IAM 200 mM
and to complete protein digestion with 2 μg of Trypsin (Sigma-
Aldrich Inc., St. Louis, MO, United States). The peptide digests
were desalted on the Discovery® DSC-18 solid phase extraction
(SPE) 96-well plate (25 mg/well) (Sigma-Aldrich Inc., St. Louis,
MO, United States). The SPE plate was preconditioned with 1 mL
of acetonitrile and 2 mL of water. After loading the sample, the
SPE was washed with 1 mL of water. The adsorbed proteins were
eluted with 800 μl of acetonitrile:water (80:20). After the desalting
process, the sample was vacuum-evaporated and reconstituted in
mobile phase for the analysis.
4.7 Proteomics Analysis and Data
Processing
The digested peptides were analyzed with an EASY nano-LC
1200 system (Thermo Scientific, Milano, Italy) coupled to a
5600+ TripleTOF system (AB Sciex, Concord, Canada). The
liquid chromatography parameters were as follows: analytical
column Acclaim PepMap C18 2 μm 75µm x 150 mm and
injection volume 2 μl. The flow rate was 300 nl/min, phase
A was 0.1% formic acid/water and phase B was 80%
acetonitrile/0.1% formic acid/20% water. A two hours
gradient was used (3–45%). For identification purposes the
mass spectrometer analysis was performed using a mass range
of 100–1600 Da (TOF scan with an accumulation time of
0.25 s), followed by a MS/MS product ion scan from 400 to
1250 Da (accumulation time of 5.0 ms) with the abundance
threshold set at 30 cps (40 candidate ions can be monitored
during every cycle). The ion source parameters in electrospray
positive mode were set as follows: curtain gas (N2) at 30 psig,
nebulizer gas GAS1 at 25 psig, ionspray floating voltage (ISFV)
at 2700 V, source temperature at 90°C and declustering
potential at 85 V.
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For label-free quantification, samples were then subjected to
cyclic data independent analysis (DIA) of the mass spectra, using
a 25-Da window. A 50 ms survey scan (TOF-MS) was performed,
followed by MS/MS experiments on all precursors. These MS/MS
experiments were performed in a cyclic manner using an
accumulation time of 40 ms per 25-Da swath (36 swaths in
total) for a total cycle time of 1.5408 s. The ions were
fragmented for each MS/MS experiment in the collision cell
using the rolling collision energy. The MS data were acquired
with Analyst TF 1.7 (SCIEX, Concord, Canada).
The validation phase was performed using a micro-LC Eksigent
Technologies (Dublin, United States) system with a stationary phase
of a Halo Fused C18 column (0.5 × 100mm, 2.7 μm; Eksigent
Technologies, Dublin, United States). The mobile phase was a
mixture of 0.1% (v/v) formic acid in water (A) and 0.1% (v/v)
formic acid in acetonitrile (B), eluting at a flow-rate of 15.0 μl min −1
at an increasing concentration of solvent B from 2 to 40% in 30min.
Samples used to generate the SWATH-MS (Sequential window
acquisition of all theoretical mass spectra) spectral library were
subjected to the traditional data-dependent acquisition (DDA): the
mass spectrometer analysis was performed using amass range of 100-
500Da (TOF scanwith an accumulation time of 0.25 s), followed by a
MS/MS product ion scan from 200 to 1250Da (accumulation time of
5.0ms) with the abundance threshold set at 30 cps (35 candidate ions
can bemonitored during every cycle). Samples were then subjected to
cyclic data independent analysis (DIA) of the mass spectra, using a
25-Da window. A 50ms survey scan (TOF-MS) was performed,
followed by MS/MS experiments on all precursors. These MS/MS
experiments were performed in a cyclic manner using an
accumulation time of 40ms per 25-Da swath (36 swaths in total)
for a total cycle time of 1.5408 s. The ions were fragmented for each
MS/MS experiment in the collision cell using the rolling collision
energy. The MS data were acquired with Analyst TF 1.7 (SCIEX,
Concord, Canada).
The mass spectrometry files were searched using Protein Pilot
(AB SCIEX, Concord, Canada) and Mascot (Matrix Science Inc.,
Boston, United States). Samples were input in the Protein Pilot
software v. 4.2 (AB SCIEX, Concord, Canada), with the following
parameters: cysteine alkylation, digestion by trypsin, no special
factors and False Discovery Rate at 1%. The UniProt Swiss-Prot
reviewed database containing human proteins (version 01/02/
2018, containing 42271 sequence entries) and SARS-CoV-2
(version 28/04/2020, containing 13175 sequence entries) The
Mascot search was performed on Mascot v. 2.4, the digestion
enzyme selected was trypsin, with 2 missed cleavages and a search
tolerance of 50 ppm was specified for the peptide mass tolerance,
and 0.1 Da for the MS/MS tolerance. The charges of the peptides
to search for were set to 2 +, 3 + and 4 +, and the search was set on
monoisotopic mass. The instrument was set to ESI-QUAD-TOF
and the following modifications were specified for the search:
carbamidomethyl cysteines as fixed modification and oxidized
methionine as variable modification (Dalla Pozza et al., 2017;
Dalle Carbonare et al., 2018).
The quantification was performed by integrating the extracted
ion chromatogram of all the unique ions for a given peptide. The
quantification was carried out with PeakView 2.2 and
MarkerView 1.2. (Sciex, Concord, ON, Canada). Six peptides
per protein and six transitions per peptide were extracted from
the SWATH files. Shared peptides were excluded as well as
peptides with modifications. Peptides with FDR lower than
1.0% were exported in MarkerView for the t-test.
Statistical analysis and related graphical representations were
done using GraphPad Prism v. 8 and MetaboAnalyst software
(www.metaboanalyst.org). Ingenuity Pathways Analysis (IPA)
software (Qiagen, Redwood City, CA, United States) and
FunRich (http://www.funrich.org) were used for bioinformatics
analysis.
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